Clinical Trials Directory

Trials / Conditions / Recurrent Gastrointestinal Carcinoid Tumor

Recurrent Gastrointestinal Carcinoid Tumor

12 registered clinical trials studyying Recurrent Gastrointestinal Carcinoid Tumor.

StatusTrialSponsorPhase
CompletedRegorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
NCT02259725
University of Southern CaliforniaPhase 2
CompletedTemsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT01155258
University of Southern CaliforniaPhase 1
CompletedErlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Nec
NCT00397384
National Cancer Institute (NCI)Phase 1
CompletedSorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00131911
National Cancer Institute (NCI)Phase 2
CompletedEverolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
NCT00655655
Mayo ClinicPhase 1
TerminatedEF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
NCT00087191
National Cancer Institute (NCI)N/A
TerminatedRomidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT00084461
National Cancer Institute (NCI)Phase 2
CompletedTemsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
NCT00093782
National Cancer Institute (NCI)Phase 2
CompletedGefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
NCT00075439
National Cancer Institute (NCI)Phase 2
CompletedBevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
NCT00055809
National Cancer Institute (NCI)Phase 2
Completed7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid
NCT00031681
National Cancer Institute (NCI)Phase 1
CompletedInterleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
NCT00004074
National Cancer Institute (NCI)Phase 1